Medial Unicondylar Knee Arthroplasty vs Total Knee Arthroplasty

Summary

In treatment of isolated medial unicondylar osteoarthritis of the knee (MU-OA), it is possible to choose between surgery with a unicondylar knee arthroplasty (UKA), or a total knee arthroplasty (TKA).

Supporters of TKA suggest that this treatment gives a more predictable and better result, whereas supporters of UKA suggest that it is unnecessary to remove decent and functional cartilage in other compartments, and also that generally the UKA gives better results under certain circumstances. If the UKA is worn out or loosens, revision surgery will be relatively easy, whereas revision-surgery after a TKA can be much more problematic.

Also, it is of great interest to measure the direct costs of these treatments. Both general hospital costs, but also costs in societal in terms of sick-days, pain-killer expenditure, and physiotherapy.

The aim of this study is to compare the results, in terms of 1) patient-reported outcomes, 2) clinical results including prosthetic survival and 3) costs.

Conditions

• Osteoarthritis, Knee

Interventions

PROCEDURE

Unicondylar Knee Arthroplasty

Incision will be midline incision, as with a TKA, for maximum security of blinding. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.

PROCEDURE

Total Knee Arthroplasty

Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.

Sponsors & Collaborators

• Naestved Hospital

  collaborator OTHER

• Vejle Hospital

  collaborator OTHER

• Aarhus University Hospital

  collaborator OTHER

• Aalborg University Hospital

  collaborator OTHER

• Svendborg Hospital

  collaborator OTHER

• Bispebjerg Hospital

  collaborator OTHER

• Randers Regional Hospital

  collaborator OTHER

• Regionshospitalet Silkeborg

  collaborator OTHER

• University Hospital, Gentofte, Copenhagen

  lead OTHER

Principal Investigators

• Anders Odgaard, Consultant · Gentofte Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

110 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2017-08-17

Primary Completion

2041-10-16

Completion

2041-10-16

Countries

• Denmark

Study Locations